Clinical Cancer Research Holland2 Stand Up to Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahama, M.
Right arrow Articles by Konishi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahama, M.
Right arrow Articles by Konishi, Y.
Clinical Cancer Research Vol. 5, 2506-2510, September 1999
© 1999 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Enhanced Expression of Tie2, Its Ligand Angiopoietin-1, Vascular Endothelial Growth Factor, and CD31 in Human Non-Small Cell Lung Carcinomas1

Makoto Takahama, Masahiro Tsutsumi, Toshifumi Tsujiuchi, Kunimoto Nezu, Keiji Kushibe, Shigeki Taniguchi, Yashige Kotake and Yoichi Konishi2

Department of Oncological Pathology, Cancer Center [M. Ta., M. Ts., T. T., Y. Kon.], Department of Surgery III [M. Ta., K. N., K. K., S. T.], Nara Medical University, Kashihara, Nara 634-8521, Japan, and Department of Free Radical Biology and Aging Research Program, Oklahoma Medical Research Foundation, Oklahoma, Oklahoma 73104 [Y. Kot.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Expression of angiogenesis-associated genes was compared in 32 primary non-small cell lung carcinoma samples (14 adenocarcinomas, 17 squamous cell carcinomas, and 1 large cell carcinoma) and paired adjacent noncancerous lung tissues using a multiprobe RNase protection assay. Levels of Tie2, angiopoietin (Ang)-1, vascular endothelial growth factor (VEGF), and CD31 mRNAs were higher in cancers than in adjacent noncancerous tissues, in contrast to the fms-like tyrosine kinase (Flt)-1, Flt-4, Tie1, thrombin receptor, endoglin, and VEGF-C, for which no differences were evident. Overexpression did not seem to differ with histological type and pathological stage. Significant positive correlations were found between mRNA expression of Ang-1 and those of Tie2 and CD31, and that of VEGF and those of Flt-1 and CD31. These findings suggest that Ang-1 and VEGF are important angiogenic factors in human non-small cell lung carcinomas.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Lung cancer is the leading cause of cancer-related death of males in both Japan3 and the United States (1) . Surgical resection remains the most effective treatment for NSCLC,4 although, at the time of diagnosis, the majority of patients present with advanced-stage disease that is no longer amenable to curative therapy (2) . Indeed, a large percentage of patients undergoing surgical resection ultimately die of recurrent NSCLC, due to the presence of occult metastatic sites at the time of diagnosis (3) . Attempts to improve this situation are focused on eliminating the causes, preventing the disease in high-risk groups, diagnosing lesions at an early curable stage, and developing new adjuvant and neoadjuvant protocols. Each of these strategies has met with limited success. Recently, there have been intense studies of molecular abnormalities involving dominant and recessive oncogenes in clinically evident lung cancers (4, 5, 6) , targeting biomarkers for early detection, due to chemotherapeutic response and gene therapy. Changes in angiogenic factors that contribute to NSCLC progression, some as independent predictors of prognosis, are particularly important in this context (7, 8, 9) .

Tie1 and Tie2 (tek) are members of the endothelial cell-specific receptor tyrosine kinase family (10 , 11) , essential for formation of the embryonic vasculature (12) . They are up-regulated in the vascular endothelium of metastatic melanomas (13) , brain tumors (14) and mammary carcinomas (15) . A ligand for the Tie1 receptor has not yet been identified, but ligands for Tie2, Ang-1, and Ang-2 have recently been shown to be essential for normal vascular development in the mouse (16 , 17) . Whether Tie2 and Ang-1 might be up-regulated in vessels of lung neoplasms has not been addressed, to our knowledge. The recently developed multiprobe RPA has advantages for simultaneous investigation of mRNA expression of several genes. In the present study, it was used to examine the expression of 10 angiogenesis-associated factors in human NSCLC. In addition to Tie1, Tie2, and Ang-1, VEGF, a well-established angiogenic factor (18 , 19) , and its receptors VEGF receptor-1/Flt-1 and VEGF receptor-2/fetal liver tyrosine kinase-1 were included because they have been reported to be up-regulated in human (7 , 8 , 20) and rat (21) NSCLCs. CD31 was also studied as a marker for vascularity (22) .


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients and Tissue Samples.
Primary NSCLC tissues obtained from 32 patients undergoing surgery in Nara Medical University Hospital between April 1998 and December 1998 were frozen in liquid nitrogen and stored at -80°C until use. Data for histological types and details for sex, age distribution, and pathological stages are summarized in Table 1Citation . The histology and pathological stage were classified according to General Rules for Clinical and Pathological Recording of Union International Contre le Cancer (23) . Noncancerous tissues adjacent to tumors were also frozen in liquid nitrogen and stored at -80°C. Total RNA was extracted from each sample using an ISOGENE kit (Nippon Gene, Toyama, Japan), as described previously (21) .


View this table:
[in this window]
[in a new window]

  		Table 1 Histological types and pathological stages of NSCLC

 
RPA for Angiogenesis-associated mRNA.
A panel of angiogenesis-associated mRNA species were detected using a multiprobe protection assay system (RiboQuant, PharMingen, San Diego, CA). Radiolabeled probes were synthesized from DNA templates containing a T7 RNA polymerase promoter (PharMingen), transcribed in the presence of 100 µCi [{alpha}-32P] dCTP to yield radioactive probes of defined sizes. Probes were hybridized with 5 µg of total RNA, then samples were treated with RNase A and T1 to digest single-stranded RNA. Intact double-stranded RNA hybrids were resolved on 5% polyacrylamide/7 M urea gels at 50 W for 70 min. Dried gels were analyzed for band locations and PSL values with a BAS 1000 Phospho Imaging Analyzer (Fuji Photo Film Co., Ltd., Minato-ku, Tokyo, Japan). Within each sample, the intensity of each angiogenesis-associated mRNA band was divided by the sum of the L32 + GAPDH bands. The size of each band was analyzed in terms of its migration distance against a plotted standard curve of migration distance versus log nucleotide length for each undigested probe (RiboQuant, Instruction manual, 5th edition, April 1998, PharMingen). The resulting value for each mRNA species was then expressed as a percentage of the average for the parameter. Finally, dried gels were redeveloped overnight by traditional autoradiography.

Statistics.
Statistical analyses were performed using a personal computer, basically as described previously elsewhere (24) . To assess the statistical significance of differences in angiogenesis-associated mRNA species between cancer and noncancer lung specimens, the Mann-Whitney nonparametric test was applied. To assess relationships between two specified factors, Pearson’s correlation coefficients were obtained with linear trends also determined using the data generated in the ANOVA. Significant differences from zero of the slope of each regression function were assessed using ANOVA tables. Lack of significant departure from linearity for each regression function was confirmed doubly by a Runs test and a test using the ANOVA table.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
The results of the multiprobe RPA analysis are depicted in Fig. 1Citation . The range of PSL values was from 7.29–979.3, therefore, all values quantified could be analyzed in the linear range. The PSL values for angiogenesis-associated gene expression are summarized in Table 2Citation . Four angiogenesis-associated gene products, Tie2, Ang-1, CD31, and VEGF were increased in cancers, the average magnitudes being 1.3-fold for Tie2, 3.9-fold for Ang-1, 1.5-fold for CD31, and 1.4-fold for VEGF. Expression of VEGF-C mRNA was not detected in any of the samples examined. Correlations between Ang-1 mRNA and Tie2 mRNA, and Ang-1 mRNA and CD31 mRNA are shown in Fig. 2, A and BCitation , respectively. A clear relationship was observed between Ang-1 mRNA and Tie2 mRNA expression (r = 0.98, P < 0.0001). The correlation coefficient between Ang-1 and CD31 mRNA expression was also significant statistically (r = 0.47, P < 0.0001), but with a significant departure from linearity (P < 0.0001). Correlations between VEGF mRNA and CD31 mRNA, and VEGF mRNA and Flt-1 mRNA are shown in Fig. 3, A and BCitation , respectively. A clear relationship was observed between VEGF mRNA and CD31 mRNA expression (r = 0.43, P = 0.0003). Although the correlation coefficient between VEGF mRNA and Flt-1 mRNA expression was also significant statistically (r = 0.79, P < 0.0001), there was again a significant departure from linearity (P = 0.019). Overexpression of Tie2, Ang-1, CD31, and VEGF and the correlations among Tie2 and Ang-1 or VEGF and CD31 did not differ with the histological type or pathological stage of NSCLCs.



View larger version (130K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Representative autoradiogram with multiprobe RPA. Increased expression of Tie2, CD31, Ang-1, and VEGF is apparent in lung cancerous tissues compared with levels in adjacent noncancerous tissues. Lanes assigned are as: Cases 30, 32, and 33, squamous cell carcinomas; Case 31, large cell carcinoma; Case 34, adenocarcinoma. Ca, cancerous tissue; N, noncancerous tissue; TR, thrombin receptor; Endg, endoglin; L32, L32 rRNA.

 

View this table:
[in this window]
[in a new window]

  		Table 2 PSL values for gene expression in 32 paired cases of NSCLCs and adjacent noncancerous tissues

 


View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Correlations between Ang-1 mRNA expression and those of Tie2 mRNA (A) and CD31 mRNA (B). A, the difference from zero of the slope of the regression function was significant (r = 0.98, P < 0.0001) with no significant departure from linearity [Y = (1.03) x -0.01]. B, the difference from zero of the slope of the regression function was significant (r = 0.47, P < 0.0001), but there was significant departure from linearity (P < 0.0001). a Normalized for the L32+GAPDH values.

 


View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Correlations between VEGF mRNA expression and those of CD31 mRNA (A) and Flt-1 mRNA (B). A, the difference from zero of the slope of the regression function was significant (r = 0.43, P = 0.0003) with no significant departure from linearity [Y = (0.60) x +3.24]. B, the difference from zero of the slope of the regression function was significant (r = 0.79, P < 0.0001), but there was significant departure from linearity (P = 0.019). a Normalized for the L32+GAPDH values.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Angiogenesis, the sprouting of new blood vessels from preexisting ones, is a complex process involving the interactions of a magnitude of angiogenesis-associated genes (25, 26, 27, 28) . It is well known that angiogenic factors contribute to development and progression of solid tumors (26 , 29) . The present finding of overexpression and correlation of mRNA levels of both Tie2 and Ang-1 in NSCLC is indicative of activation of the Tie2/Ang-1 system (16) . The results for VEGF and CD31 are further suggestive of angiogenesis in NSCLC (18 , 22) .

Angiopoietins (Ang-1 and Ang-2) constitute a novel family of endothelial growth factors that are ligands for Tie2 (9, 10, 11, 12 , 14 , 30) . Whereas Ang-1 can stimulate endothelial sprouting in vitro (31) , however, exposure of Tie2 in cultured endothelial cells to either Ang-1 or Ang-2, unlike the case with other endothelial growth factors, does not produce a mitogenic response (9) . Unfortunately, we could not analyze the expression of Ang-2 because of the lack of an appropriate probe, but this warrants further investigation.

VEGF, first detected as a factor inducing microvascular permeability (32) and extravasation of various proteins to metastases, also acts as an endothelial cell mitogen (33) . Previously, we reported frequent expression of VEGF detected by immunohistochemistry in human NSCLCs (34) . The present results, thus, provide confirmation at the mRNA level with a molecular biological technique.

The realization that multiple pathways are likely to be required for the assembly of a functional vasculature has broad implications for therapeutic modulation. For example, it has already been shown that blocking either the Tie2/Ang-1 pathway or the VEGF pathway can inhibit tumor angiogenesis (35 , 36) . Because Tie2/Ang-1 and VEGF function at different stages of vascular development, it seems likely that inhibiting both pathways may be more effective than inhibiting each individually (37) . Moreover, our results suggest the possibility that antibody therapy against each of these may improve the outcome with this otherwise generally refractory cancer.


   ACKNOWLEDGMENTS
 
We express our gratitude to Dr. Malcolm Moore for English correction and careful reading of this manuscript; to Megumi Inagaki-Yamaguchi, Hiroko Masuda, and Sachiko Nakai for technical assistance; and to Yumi Horikawa, Rie Maeda, Nami Makimura, and Yuko Yoshinaka for editorial assistance.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by Grants-in-Aid for Cancer Research (designated 7-1 and 8-2 to Y. Kon. and 10-4 to T. T.) and for Scientific Research Expenses for Health and Welfare Programs, 2nd-Term Comprehensive 10-Year Strategy for Cancer Control, Cancer Prevention, from the Ministry of Health and Welfare of Japan (to Y. Kon.), and by Grant-in-Aid 08264108 (to Y. Kon.) for Scientific Research in Priority Areas, Cancer Research, from the Ministry of Education, Science, Sports and Culture of Japan. Back

2 To whom requests for reprints should be addressed, at the Department of Oncological Pathology, Cancer Center, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan. Phone: 81-744-22-3051, ext. 2574; Fax: 81-744-25-7308; E-mail: ykonishi{at}nmu-gw.cc.naramed-u.ac.jp Back

3 Ministry of Health and Welfare of Japan. Statistics and other data, http://mhw.go.jp/toukei/sibouritsu/mokuji.html (in Japanese). Back

4 The abbreviations used are: NSCLC, non-small cell lung carcinoma; Ang, angiopoietin; Flt, fms-like tyrosine kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PSL, phosphostimulating luminescence; RPA, RNase protection assay; VEGF, vascular endothelial growth factor. Back

Received 4/ 6/99; revised 7/ 6/99; accepted 7/ 8/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Landis, S. H., Murray, T., Bolden, A., and Wingo, P. A. Cancer statistics 1998 (published erratum appears in CA Cancer J. Clin., 48: 192, 1998). CA Cancer J. Clin., 48: 6–29 1998.
  2. Ahrendt S. A., Chow J. T., Xu L-H., Yang S. C., Eisenberger C. F., Esteller M., Herman J. G., Wu L., Decker P. A., Jen J., Sidransky D. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl. Cancer Inst., 91: 332-339, 1999.[Abstract/Free Full Text]
  3. Naruke, T., Goya, T., Tsuchiya, R., and Suemasu, K. Prognosis and survival in resected lung carcinoma based on the new international staging system (published erratum appears in J. Thorac. Cardiovasc. Surg., 97: 350, 1989). J. Thorac. Cardiovasc. Surg., 96: 440–447, 1988.
  4. Konishi H., Takahashi T., Kozaki K., Yatabe Y., Mitsudomi T., Fujii Y., Sugiura T., Matsuda H., Takahashi T., Takahashi T. Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers. Oncogene, 17: 2095-2100, 1998.[Medline]
  5. Tomizawa Y., Nakajima T., Kohno T., Saito R., Yamaguchi N., Yokota J. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res., 58: 5478-5483, 1998.[Abstract/Free Full Text]
  6. Mao L., Lee J. S., Kurie J. M., Fan Y. H., Lippman S. M., Lee J. J., Ro J. Y., Broxson A., Yu R., Morice R. C., Kemp B. L., Khuri F. R., Walsh G. L., Hittelman W. N., Hong W. K. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst., 89: 857-862, 1997.[Abstract/Free Full Text]
  7. Ohta Y., Endo Y., Tanaka M., Shimizu J., Oda M., Hayashi Y., Watanabe Y. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin. Cancer Res., 2: 1411-1416, 1996.[Abstract]
  8. Takanami I., Tanaka F., Hashizume T., Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res., 17: 2811-2814, 1997.[Medline]
  9. Mattern J., Koomagi R., Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int. J. Oncol., 6: 1059-1062, 1995.
  10. Schnurch H., Risau W. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial lineage. Development (Camb.), 119: 957-968, 1993.[Abstract]
  11. Maisonpierre P. C., Goldforb M., Yancopoulos G. D., Gao G. Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family. Oncogene, 8: 1631-1637, 1993.[Medline]
  12. Sato T. N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Quin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature (Lond.), 376: 70-74, 1995.[Medline]
  13. Kaipaimen A., Vlaykova T., Hatva E., Bohling T., Jekunen A., Pyrhonen S., Alitalo K. Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res., 54: 6571-6577, 1994.[Abstract/Free Full Text]
  14. Hatva E., Kaipaimen A., Jaaskelainen J., Paetau A., Haltia M., Alitalo K. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am. J. Pathol., 146: 368-378, 1995.[Abstract]
  15. Peters K. G., Coogan A., Berry D., Marks J., Iglehart J. D., Kontos C. D., Rao P., Sankar S., Trogan E. Expression of Tie2/Tek in breast tumor vasculature provides a new marker for evaluation of tumor angiogenesis. Br. J. Cancer., 77: 51-56, 1998.[Medline]
  16. Davis S., Aldrich T. H., Jones P. F., Acheson A., Compton D. L., Jain V., Ryan T. E., Bruno J., Radziejewski C., Maisonpierre P. C., Yancopoulos G. D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell, 87: 1161-1169, 1996.[Medline]
  17. Maisonpierre P. C., Suri C., Jones P. F., Bartunkova S., Wiegand S. J., Radziejewski C., Compton D., McClain J., Aldrich T. H., Papadopoulos N., Daly T. J., Davis S., Sato T. N., Yancopoulos G. D. Angiopoitin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (Washington DC), 277: 55-60, 1997.[Abstract/Free Full Text]
  18. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.[Medline]
  19. Folkman J. Antiangiogenic gene therapy. Proc. Natl. Sci. USA, 95: 9064-9066, 1998.[Free Full Text]
  20. Mattern J., Koomagi R., Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int. J. Oncol., 6: 1059-1062, 1995.
  21. Takahama M., Tsutsumi M., Tsujiuchi T., Kido A., Sakitani H., Iki K., Taniguchi S., Kitamura S., Konishi Y. Expression of vascular endothelial growth factor and its receptors during lung carcinogenesis by N-nitrosobis(2-hydroxypropyl)amine in rats. Mol. Carcinogenesis, 24: 287-293, 1999.[Medline]
  22. Yoshiji H., Kuriyama S., Yoshii J., Yamazaki M., Kikukawa M., Tsujinoue H., Nakatani T., Fukui H. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology, 28: 1489-1496, 1998.[Medline]
  23. UICC TNM Classification of Malignant Tumors Ed. 5 93-97, Wiley-Liss New York 1997.
  24. Nakae D., Kobayashi Y., Akai H., Andoh N., Satoh H., Ohashi K., Tsutsumi M., Konishi Y. Involvement of 8-hydroxyguanine formation in the initiation of rat liver carcinogenesis by low dose levels of. N-nitrosodiethylamine. Cancer Res., 57: 1281-1287, 1997.[Abstract/Free Full Text]
  25. Hanahan D. Signaling vascular morphogenesis and maintenance. Science (Washington DC), 277: 48-50, 1997.[Free Full Text]
  26. Folkman J., D’Amore P. A. Blood vessel formation: what is its molecular basis?. Cell, 87: 1153-1155, 1996.[Medline]
  27. Klagsbrun M., D’Amore P. A. Regulation of angiogenesis. Annu. Rev. Physiol., 53: 217-239, 1991.[Medline]
  28. Folkman J. Tumor angiogenesis Mendelsohn J. Howley P. Liotta L. A. Israel M. eds. . The Molecular Basis of Cancer, : 206-232, W. B. Saunders Philadelphia 1995.
  29. Craft P. S., Harris A. L. Clinical prognostic significance of tumor angiogenesis. Ann. Oncol., 5: 305-311, 1994.[Abstract/Free Full Text]
  30. Sato T. N., Qin Y., Kozak C. A., Audus K. L. tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc. Natl. Acad. Sci. USA, 90: 9355-9358, 1993.[Abstract/Free Full Text]
  31. Koblizek T. I., Weiss C., Yancopoulos G. D., Deutsch U., Risau W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol., 8: 529-532, 1998.[Medline]
  32. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Harvey V. S., Dvorak H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Washington DC), 219: 983-985, 1983.[Abstract/Free Full Text]
  33. Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Washington DC), 246: 1306-1309, 1989.[Abstract/Free Full Text]
  34. Takahama M., Tsutsumi M., Tsujiuchi T., Kido A., Okajima E., Nezu K., Tojo T., Kushibe K., Kitamura S., Konishi Y. Frequent expression of the vascular endothelial growth factor in human non-small cell lung cancers. Jpn. J. Clin. Oncol., 27: 176-181, 1998.
  35. Lin P., Polverini P., Dewhirst M., Shan S., Rao P. S., Peters K. G. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie-2 in pathologic vascular growth. J. Clin. Invest., 100: 2072-2078, 1997.[Medline]
  36. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (Lond.), 362: 841-844, 1993.[Medline]
  37. Asahara T., Chen D., Takahashi T., Fujikawa K., Kearney M., Magner M., Yancopoulos G. D., Isner J. M. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res., 83: 233-240, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 ThoraxHome page
H Kothmaier, F Quehenberger, I Halbwedl, P Morbini, F Demirag, H Zeren, C E Comin, B Murer, P T Cagle, R Attanoos, et al.
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
Thorax, April 1, 2008; 63(4): 345 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
W. S.N. Shim, I. A.W. Ho, and P. E.H. Wong
Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis
Mol. Cancer Res., July 1, 2007; 5(7): 655 - 665.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
I. Fishel, A. Kaufman, and E. Ruppin
Meta-analysis of gene expression data: a predictor-based approach
Bioinformatics, July 1, 2007; 23(13): 1599 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. E. Fathers, C. M. Stone, K. Minhas, J. J.A. Marriott, J. D. Greenwood, D. J. Dumont, and B. L. Coomber
Heterogeneity of Tie2 Expression in Tumor Microcirculation: Influence of Cancer Type, Implantation Site, and Response to Therapy
Am. J. Pathol., December 1, 2005; 167(6): 1753 - 1762.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Chen, K. Takenaka, E. Ogawa, K. Yanagihara, Y. Otake, H. Wada, and F. Tanaka
Flt-4-Positive Endothelial Cell Density and Its Clinical Significance in Non-Small Cell Lung Cancer
Clin. Cancer Res., December 15, 2004; 10(24): 8548 - 8553.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J.-X. Chen, Y. Chen, L. DeBusk, W. Lin, and P. C. Lin
Dual functional roles of Tie-2/angiopoietin in TNF-{alpha}-mediated angiogenesis
Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H187 - H195.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
D. Chu, C. C. Sullivan, L. Du, A. J. Cho, M. Kido, P. L. Wolf, M. D. Weitzman, S. W. Jamieson, and P. A. Thistlethwaite
A new animal model for pulmonary hypertension based on the overexpression of a single gene, angiopoietin-1
Ann. Thorac. Surg., February 1, 2004; 77(2): 449 - 456.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Giuliani, S. Colla, M. Lazzaretti, R. Sala, G. Roti, C. Mancini, S. Bonomini, P. Lunghi, M. Hojden, G. Genestreti, et al.
Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis
Blood, July 15, 2003; 102(2): 638 - 645.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Tanaka, S. Ishikawa, K. Yanagihara, R. Miyahara, Y. Kawano, M. Li, Y. Otake, and H. Wada
Expression of Angiopoietins and Its Clinical Significance in Non-Small Cell Lung Cancer
Cancer Res., December 1, 2002; 62(23): 7124 - 7129.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C.S. Brock and S.M. Lee
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer
Eur. Respir. J., March 1, 2002; 19(3): 557 - 570.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. Abdulmalek, F. Ashur, N. Ezer, F. Ye, S. Magder, and S. N. A. Hussain
Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats
Am J Physiol Lung Cell Mol Physiol, September 1, 2001; 281(3): L582 - L590.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahama, M.
Right arrow Articles by Konishi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahama, M.
Right arrow Articles by Konishi, Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online